Phase II study of 506U78 [nelarabine] (NSC 686673) for patients with relapsed or refractory indolent B-cell or peripheral T-cell lymphoma.

Trial Profile

Phase II study of 506U78 [nelarabine] (NSC 686673) for patients with relapsed or refractory indolent B-cell or peripheral T-cell lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Nelarabine (Primary)
  • Indications B cell lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 06 Aug 2007 Status changed from in progress to completed.
    • 22 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top